Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers

Journal of Veterinary Internal Medicine

Volumn 20, Issue 5, 2006, Pages 1172-1177

  Kosarek, Carrie E ^a   Hu, Xiao ^b   Couto, C Guillermo ^a   Kisseberth, William C ^a   Green, Eric M ^a   Au, Jessie L S ^b   Wientjes, M Guillaume ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Clinical trial; Dog disease; Drug resistance; Neoplasms; Osteosarcoma; Prostatic neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; SURAMIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG POTENTIATION; FEMALE; MALE; NEOPLASM; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; DOXORUBICIN; DRUG SYNERGISM; FEMALE; MALE; NEOPLASMS; NEUTROPENIA; PLATELET COUNT; SURAMIN; THROMBOCYTOPENIA;

ANIMALIA; CANIS FAMILIARIS;

EID: 33750345171     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[1172:PIEOLS]2.0.CO;2     Document Type: Article

References (33)

1. Hawking F. Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother 1978;15:289-322.
2. DeClercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Letters 1979;8:9-22.
3. Bowden CJ, Figg WD, Dawson NA, et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response. Cancer Chemother Pharmacol 1996;39:1-8.
4. Falcone A, Antonuzzo A, Danesi R, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999;86:470-476.
5. Motzer RJ, Dmitrovsky E, Miller WH, Jr., et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 1993;72:3313-3317.
6. Grossman SA, Phuphanich S, Lesser G, et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J Clin Oncol 2001;19:3260-3266.
7. Mirza MR, Jakobsen E, Pfeiffer P, et al. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol 1997;36:171-174.
8. La Rocca RV, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology 1990;40:954-960.
9. Motzer RJ, Nanus DM, O'Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 1992;52:5775-5779.
10. Myers C, Cooper M, Sein C, et al. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-889.
11. Rapoport BL, Falkson G, Raats JI, et al. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study. Ann Oncol 1993;4:567-573.
12. Rosen PJ, Mendoza EF, Landaw EM, et al. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy. J Clin Oncol 1996;14:1626-1636.
13. Scher HI. Suramin: Here to stay!? J Natl Cancer Inst. 1993;85:594-597.
14. Song S, Wientjes MG, Gan Y, et al. Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-8663.
15. Hensey CE, Boscoboinik D, Azzi A. Suramin, an anticancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 1989;258:156-158.
16. Takano S, Gately S, Neville ME, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-2660.
17. Wade TP, Kasid A, Stein CA, et al. Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res 1992;53:195-198.
18. Song S, Wientjes MG, Walsh C, et al. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 2001;61:6145-6150.
19. Song S, Yu B, Wei Y, et al. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 2004;10:6058-6065.
20. Xin Y, Lyness G, Chen D, et al. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol 2005;174:322-327.
21. Zhang Y, Song S, Yang F, et al. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 2001;299:426-433.
22. Villalona-Calero MA, Wientjes MG, Otterson GA, et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003;9:3303-3311.
23. Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 1994;12:166-175.
24. Reyno LM, Egorin MJ, Eisenberger MA, et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995;14:2187-2195.
25. Chen CT. Development of drugs for human prostate cancer. Columbus, OH: Ohio State University; 1997. Thesis.
26. Gan Y, Wientjes MG, Badalament RA, et al. Pharmacodynamics of doxorubicin in human bladder tumors. Clin Cancer Res 1996;2:1275-1283.
27. Sheafor SE, Couto CG, Ward H, et al. Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies. J Vet Intern Med 2000;14:86-89.
28. Thamm DH, MacEwen EG, Phillips BS, et al. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother Pharmacol 2002;49:251-255.
29. Kassack M, Nickel P. Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. J Chromatogr B Biomed Appl 1996;686:275-284.
30. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
31. Mauldin GE, Fox PR, Patnaik AK, et al. Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med 1992;6:82-88.
32. Myers CE, Chabner BA. Anthracyclines. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice, Philadelphia, PA: Lippincott; 1990:356-381.
33. Tu SM, Pagliaro LC, Banks ME, et al. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 1998;4:1193-1201.